Massachusetts Institute of Technology
Sign in

Innovation in Manufacturing and Distribution Systems (Part Three)

08/18/2005 1:30 PM Wong Auditorium
Charles L. Cooney, SM '67, PhD '70, Professor of Chemical and Biochemical Engieering; Co-Director, Program on the Pharmaceutical Industry; Mark R. Bamforth, Senior Vice President, Corporate Operations and Pharmaceutical ; Genzyme Corporation; Peter Walsh, Director of Business Development, UPS Consulting ; Abbot Weiss, Senior Lecturer; MIT Center for Transportation and Logistics ; ; Daniel W. Engels, Director, R.F.I.D. Healthcare Initiative ;

Description: Genzyme is a leader in personalized medicine, as Mark Bamforth demonstrates. For instance, the company collects cartilage from a single patient, grows it in the lab, and sends it back securely to that same patient. The system, says Bamforth, tolerates "no mix ups." But the company also deals in drugs sent to hundreds of thousands of kidney dialysis patients. Each kind of product must adhere to a specific kind of manufacturing and distribution process, and the regulations of the FDA and other countries. Bamforth must navigate "a complexity and diversity of supply chains."

Peter Walsh works behind the scenes at UPS, making sure those brown trucks deliver to the right location at the right time. He believes that "healthcare is a good 20 to 30 years behind other industries" in terms of getting the goods from supplier to manufacturer to consumer. "We see in big pharma a silo approach. That needs to change ' and means sharing of information scary to think of in this industry."

Abbott Weiss sees in pharmaceuticals "a highly fragmented set of supply chains" at a time when globalization poses increased risks, such as theft and diversion, and cost pressures. He describes working at Polaroid, and shipping out 120 million packs of film a year, with 140 countries each requiring different labeling. "Exception management is the rule in supply chains," says Weiss. And unlike film, there are "life and death implications of getting the right medicine at the right time and right place." The good news is that much of the technology for solving tracking and distribution problems already exists, Weiss says.

One such technology, radio frequency identification (RFID), is a good first enabling step for pharmaceutical makers, says Daniel Engels. "If I know what I have and where it is, I can do something about it." The critical problem will be "asset visibility," communicating this unique product information to suppliers and customers. And this kind of tagging will prove especially difficult for generic or bulk drugs, sent through distributors. The "end game" is information sharing.



Host(s): Sloan School of Management, MIT Center for Biomedical Innovation

Tape #: T20182, T20183 and T20184.

Comments (0)

It looks like no one has posted a comment yet. You can be the first!

You need to log in, in order to post comments.

MIT World — special events and lectures

MIT World — special events and lectures

Category: Events | Updated over 1 year ago

Created
December 12, 2011 20:32
Category
Tags
License
All Rights Reserved (What is this?)
Additional Files


Viewed
4358 times

More from MIT World — special events and lectures

The Medium Doesn't Matter

The Medium Doesn't Matter

Added over 5 years ago | 00:52:38 | 10771 views

Building Resilient Infrastructure to Combat Terrorism: Lessons from September 11th

Building Resilient Infrastructure t...

Added over 5 years ago | 01:06:00 | 4121 views

Nanofabrication Technology: A View of the Future

Nanofabrication Technology: A View ...

Added over 5 years ago | 01:16:00 | 6803 views

The Brain Basis of Human Vision

The Brain Basis of Human Vision

Added over 5 years ago | 01:12:00 | 5410 views

Learning to See in the Dark: The Roots of Ethical Resistance

Learning to See in the Dark: The Ro...

Added over 5 years ago | 01:10:00 | 11569 views

2004 Nobel Colloquium

2004 Nobel Colloquium

Added over 5 years ago | 01:25:00 | 4462 views